April 10, 2025, 8:00 AM-5:00 PM
Neuroscience Center
Register at: Type 1 Diabetes Biomarkers Meeting
The precise and accurate quantification of proteins and peptides that are involved in diabetes pathogenesis will help facilitate research into disease mechanisms and ultimately improve the diagnosis, prognosis, and therapeutic management of patients with diabetes. NIDDK recently funded several projects that aim to use targeted mass spectrometry to quantify human plasma/serum proteins and peptides of interest to the obesity and diabetes clinical research community. During this symposium, members of the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium will provide an overview of the recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers will highlight the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.
During this symposium, members of the Targeted Mass spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium will provide an overview of the recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers will highlight the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.
|
7:30-8:00 am |
Light breakfast |
|
8:00-8:10 am |
Salvatore Sechi, Ph.D., NIDDK/NIH History and purpose of TaMADOR |
|
8:10-8:20 am |
Will Cefalu, M.D. NIDDK/NIH Welcome and Introduction |
|
8:20-9:00 am |
Marian Rewers, M.D., Ph.D., University of Colorado An Overview of Islet Autoantibody Testing Methods |
|
9:00-9:25 am |
Michael MacCoss, Ph.D., University of Washington Plasma Proteomics for the Assessment of Patient Response to Therapy |
|
9:25-9:50 am |
Lorenz Nierves, Ph.D., PNNL Mass Spectrometry-based discovery of prohormone processing products as potential novel biomarkers |
|
9:50-10:00 am |
Coffee Break |
|
10:00-10:35 am |
Kuanysh Kabytaev, Ph.D., University of Missouri Standardization of C-peptide/Insulin |
|
10:35-11:00 pm |
Jun Qu, Ph.D., University of Buffalo A multiplex assay for proinsulin proteoforms: assay development and optimization |
|
11:00-11:25 pm |
Katrina Forrest, University of Washington Progress Toward Novel Assays for Alternative Proglucagon Fragments |
|
11:25-12:00 pm |
Carmella Evans-Molina, M.D., Ph.D., University of Indiana Biomarkers in Clinical Diabetes Research |
|
12:00-12:45 pm |
Lunch |
|
12:45-1:10 pm |
Weijun Qian, Ph.D., PNNL Exploratory assessment of proinsulin proteoforms as biomarkers of beta cell stress in T1D |
|
1:10-1:35 pm |
Andy Hoofnagle, MD PhD, University of Washington Quantification of Proinsulin in Human Plasma |
|
1:35-2:10 pm |
Rob Fitzgerald, Ph.D., University of California, San Diego A Clinical Lab Perspective of a Successful Biomarker |
|
2:10-2:25 pm |
Coffee Break |
|
2:25-2:50 pm |
Weijun Qian, Ph.D., PNNL; and Jun Qu, Ph.D., University of Buffalo Assessments of novel methods for biomarker discovery |
|
2:50-3:15 pm |
Jessica Becker, M.S., University of Washington Interlaboratory Transfer of a Novel Assay for Glucagon and Oxyntomodulin |
|
3:15-3:55 pm |
Bruce Verchere, Ph.D., University of British Columbia Islet prohormone processing: proIAPP forms as novel beta cell biomarkers in diabetes |
|
4:00-5:00 pm |
Closed: Expert Panel / Investigators meeting |
